What is the story about?
India's apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has significantly stepped up its surveillance of the supply chain of GLP-1-based weight-loss drugs, amid rising concerns over their unauthorised sale, misuse, and misleading promotion across the country.
Sources told CNBC-TV18 that the regulator has already conducted inspections at 49 entities, including online pharmacy warehouses, wholesalers, retailers, and wellness or slimming clinics. These inspections, carried out across multiple regions, were aimed at identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing of these drugs.
Notices issued, violations flagged
Following the inspections, CDSCO has issued notices to several entities for irregularities in the sale and promotion of GLP-1 drugs. The move signals a sharper enforcement stance as the regulator responds to growing concerns over the easy availability of these medicines outside regulated medical channels.
The heightened scrutiny comes against the backdrop of multiple generic variants of GLP-1 drugs entering the Indian market, which has significantly increased their accessibility through retail pharmacies, online platforms, and even wellness clinics offering weight-loss solutions.
Government flags health risks, steps up surveillance
In an official statement issued on March 24, the government said the Drugs Controller of India, in coordination with state regulators, has intensified regulatory surveillance to ensure ethical pharmaceutical practices in the supply chain of GLP-1 drugs.
Authorities have raised red flags over the on-demand availability of these drugs without adequate medical supervision, warning that such misuse could lead to serious adverse health effects and complications.
"Taking cognisance of the situation, targeted actions have been initiated to curb malpractices and prevent unauthorised sales and use," the statement noted.
Advisory bans surrogate ads, off-label promotion
As part of its regulatory push, CDSCO had earlier, on March 10, issued a comprehensive advisory to all manufacturers, explicitly:
The regulator reiterated that GLP-1 drugs are prescription-only medicines and must be used strictly under the supervision of qualified specialists, including endocrinologists, internal medicine practitioners, and, for certain indications, cardiologists.
Patient safety at the centre
Emphasising that patient safety remains paramount, the regulator cautioned that unsupervised use of GLP-1 drugs — often sought for rapid weight loss — can pose significant health risks.
Citizens have been advised to avoid self-medication and use such treatments only under proper clinical guidance.
Strict action for non-compliance
CDSCO has made it clear that regulatory surveillance will continue to intensify in the coming weeks, with a warning of strict action against violators. This could include:
The regulator's latest actions underscore a zero-tolerance approach to unauthorised sales, misuse, and unethical promotion practices in the fast-growing market for weight-loss drugs.
Sources told CNBC-TV18 that the regulator has already conducted inspections at 49 entities, including online pharmacy warehouses, wholesalers, retailers, and wellness or slimming clinics. These inspections, carried out across multiple regions, were aimed at identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing of these drugs.
Notices issued, violations flagged
Following the inspections, CDSCO has issued notices to several entities for irregularities in the sale and promotion of GLP-1 drugs. The move signals a sharper enforcement stance as the regulator responds to growing concerns over the easy availability of these medicines outside regulated medical channels.
The heightened scrutiny comes against the backdrop of multiple generic variants of GLP-1 drugs entering the Indian market, which has significantly increased their accessibility through retail pharmacies, online platforms, and even wellness clinics offering weight-loss solutions.
Government flags health risks, steps up surveillance
In an official statement issued on March 24, the government said the Drugs Controller of India, in coordination with state regulators, has intensified regulatory surveillance to ensure ethical pharmaceutical practices in the supply chain of GLP-1 drugs.
Authorities have raised red flags over the on-demand availability of these drugs without adequate medical supervision, warning that such misuse could lead to serious adverse health effects and complications.
"Taking cognisance of the situation, targeted actions have been initiated to curb malpractices and prevent unauthorised sales and use," the statement noted.
Advisory bans surrogate ads, off-label promotion
As part of its regulatory push, CDSCO had earlier, on March 10, issued a comprehensive advisory to all manufacturers, explicitly:
- Prohibiting surrogate advertisements
- Banning indirect or misleading promotional practices
- Warning against off-label usage promotion
The regulator reiterated that GLP-1 drugs are prescription-only medicines and must be used strictly under the supervision of qualified specialists, including endocrinologists, internal medicine practitioners, and, for certain indications, cardiologists.
Patient safety at the centre
Emphasising that patient safety remains paramount, the regulator cautioned that unsupervised use of GLP-1 drugs — often sought for rapid weight loss — can pose significant health risks.
Citizens have been advised to avoid self-medication and use such treatments only under proper clinical guidance.
Strict action for non-compliance
CDSCO has made it clear that regulatory surveillance will continue to intensify in the coming weeks, with a warning of strict action against violators. This could include:
- Cancellation of licenses
- Monetary penalties
- Prosecution under applicable laws
The regulator's latest actions underscore a zero-tolerance approach to unauthorised sales, misuse, and unethical promotion practices in the fast-growing market for weight-loss drugs.
